COVID-19 Drives Increased Pharma-Bio Diagnostics Facility Spending

COVID-19 Drives Increased Pharma-Bio Diagnostics Facility Spending

COVID-19 Drives Increased Pharma-Bio Diagnostics Facility Spending


Attachment: dia

SUGAR LAND--April 12, 2021--Researched by Industrial Info Resources (Sugar Land, Texas)--The diagnostics cohort of the Pharmaceutical-Biotech Industry, namely in vitro diagnostics (IVD) tests, are considered medical devices. Diagnostic products may be reagents, techniques, instruments, or a combination of these used in vitro for the examination of specimens such as blood, urine or tissue with the goal of obtaining a diagnosis from assays in a controlled environment outside a living organism.

Industrial Info's Pharma/Bio group is currently tracking 93 active U.S. and Canada diagnostics substances projects with a total investment value of $1.56 billion.

Subscribe Now!(All Fields Required)

Standard Membership - Free